A modified fragment of human growth hormone (hGH 176-191) studied for lipolysis and body composition support, without affecting blood glucose or IGF-1 levels. Physician-reviewed. Prescription required.
AOD 9604 is a small peptide derived from the C-terminal fragment of human growth hormone (hGH). Unlike full-length GH, AOD 9604 is designed to stimulate fat metabolism without affecting blood sugar or growth of other tissues. Its primary action is on lipid metabolism pathways, rather than traditional GH–IGF-1 signaling.
AOD-9604 targets fat metabolism through direct lipolysis and inhibition of lipogenesis, without the blood-sugar or growth effects of full-length GH. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Lipolysis activation | Breakdown of stored fat |
| Inhibition of lipogenesis | Reduces fat storage |
| Selective GH fragment | Minimal IGF-1 effects |
| Tissue repair (minor) | Slight cartilage/ECM support |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with AOD-9604 protocol candidates in clinical practice:
Fat Loss Protocol
Individuals with physician-confirmed adiposity seeking targeted metabolic support.
Insulin Sensitivity
Individuals with metabolic syndrome components seeking targeted fat-metabolism support.
Endurance & Energy
Athletes or executives seeking body-composition and metabolic efficiency support.
Combination Protocol
Patients adding AOD-9604 to a physician-reviewed metabolic stack.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
300 mcg–1.2 mg/day
Administration
Subcutaneous injection
Duration
12–24 weeks (physician-determined)
Frequency
Daily to 3x weekly (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.